Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study

Conference Reports for NATAP

HIV Glasgow 2026
8-11 November


Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study

	Glasgow 2026 Nov 8-11 Milosz Parczewski